Somewhat Favorable Press Coverage Somewhat Unlikely to Impact bluebird bio (BLUE) Stock Price
News stories about bluebird bio (NASDAQ:BLUE) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. bluebird bio earned a news impact score of 0.22 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.5665516660072 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Maxim Group Analysts Give bluebird bio, Inc. (BLUE) a $170.00 Price Target (americanbankingnews.com)
- Celgene CAR-T Therapy Gets Breakthrough Therapy Designation (nasdaq.com)
- bluebird bio (BLUE) Says First Patient Treated in Northstar-3, Phase 3 Study of LentiGlobin in Patients with TDT (streetinsider.com)
- Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell (newkerala.com)
- ETFs with exposure to bluebird bio, Inc. : November 16, 2017 (finance.yahoo.com)
Shares of bluebird bio (NASDAQ:BLUE) traded up $3.05 during trading hours on Friday, reaching $163.20. 482,407 shares of the company’s stock traded hands, compared to its average volume of 842,571. bluebird bio has a one year low of $56.80 and a one year high of $164.80.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. During the same period in the previous year, the business posted ($2.07) EPS. The firm’s quarterly revenue was up 397.4% compared to the same quarter last year. equities research analysts forecast that bluebird bio will post -6.68 EPS for the current fiscal year.
BLUE has been the topic of a number of research reports. Cantor Fitzgerald reissued a “sell” rating and issued a $39.00 price objective on shares of bluebird bio in a research note on Monday, July 24th. Sanford C. Bernstein initiated coverage on shares of bluebird bio in a research note on Thursday, July 27th. They issued a “market perform” rating and a $109.00 price objective on the stock. BidaskClub cut shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. BMO Capital Markets reissued a “buy” rating and issued a $108.00 price objective on shares of bluebird bio in a research note on Friday, August 4th. Finally, Morgan Stanley increased their price objective on shares of bluebird bio from $103.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 7th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $131.05.
TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/11/19/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-bluebird-bio-blue-stock-price.html.
In other news, insider Nick Leschly sold 25,667 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $115.18, for a total transaction of $2,956,325.06. Following the completion of the sale, the insider now owns 339,368 shares of the company’s stock, valued at $39,088,406.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeffrey T. Walsh sold 35,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $151.38, for a total transaction of $5,298,300.00. Following the sale, the insider now directly owns 62,305 shares of the company’s stock, valued at approximately $9,431,730.90. The disclosure for this sale can be found here. Insiders have sold 193,168 shares of company stock valued at $25,558,003 in the last three months. Corporate insiders own 3.90% of the company’s stock.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.